Key points are not available for this paper at this time.
There is a clinical need for 18F-labeled somatostatin analogs for the imaging of neuroendocrine tumors (NET), given the limitations of using 68GaGa-DOTA-peptides, particularly with regard to widespread accessibility. We have shown that 18Ffluoroethyl-triazole-Tyr3-octreotate (18FFET-βAG-TOCA) has favorable dosimetry and biodistribution. As a step toward clinical implementation, we conducted a prospective, noninferiority study of 18FFET-βAG-TOCA PET/CT compared with 68GaGa-DOTA- peptide PET/CT in patients with NET. Methods: Forty-five patients with histologically confirmed NET, grades 1 and 2, underwent PET/CT imaging with both 18FFET-βAG-TOCA and 68GaGa-peptide performed within a 6-mo window (median, 77 d; range, 6–180 d). Whole-body PET/CT was conducted 50 min after injection of 165 MBq of 18FFET-βAG-TOCA. Tracer uptake was evaluated by comparing SUVmax and tumor-to-background ratios at both lesion and regional levels by 2 unblinded, experienced readers. A randomized, blinded reading of both scans was also then undertaken by 3 experienced readers, and consensus was assessed at a regional level. The ability of both tracers to visualize liver metastases was also assessed. Results: A total of 285 lesions were detected on both imaging modalities. An additional 13 tumor deposits were seen in 8 patients on 18FFET-βAG-TOCA PET/CT, and 68GaGa-DOTA-peptide PET/CT detected an additional 7 lesions in 5 patients. Excellent correlation in SUVmax was observed between both tracers (r = 0.91; P max across regions, except in the liver, where the median tumor-to-background ratio of 18FFET-βAG-TOCA was significantly lower than that of 68GaGa-DOTA-peptide (2.5 ± 1.9 vs. 3.5 ± 2.3; P Conclusion: 18FFET-βAG-TOCA was not inferior to 68GaGa-DOTA-peptide in visualizing NET and may be considered in routine clinical practice given the longer half-life and availability of the cyclotron-produced fluorine radioisotope.
Dubash et al. (Thu,) studied this question.